ArticleOncoimmunology2021
Combination of EP
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- Metabolic immune checkpoints (MICs) in cancer: from molecular mechanisms to challenges and opportunities in clinical translation.Signal transduction and targeted therapy · 2026Review
- Metabolic-epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment.Experimental & molecular medicine · 2026Review
- Ablation of prostaglandin ENature biomedical engineering · 2026Article
- Nervous and immune system crosstalk shapes cancer progression and treatment response.Discover oncology · 2026Review
- Engineering with EP2/EP4 knockout and IL-15 transpresentation renders stem cell-derived NK cells self-persistent and resistant to PGE2 inhibition.Frontiers in immunology · 2026Article
- The Myeloid BiomarkerInternational journal of molecular sciences · 2025Article
- Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer.BMC cancer · 2025Article
- MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy.Cancer gene therapy · 2025Review
- Immunoregulatory mechanisms of the arachidonic acid pathway in cancer.FEBS letters · 2025Review
- Targeting KRAS: from metabolic regulation to cancer treatment.Molecular cancer · 2025Review
- Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies.Theranostics · 2025Review
- Immunocytes in the tumor microenvironment: recent updates and interconnections.Frontiers in immunology · 2025Review
- Cancer cell metabolism and antitumour immunity.Nature reviews. Immunology · 2024Review
- Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4.Genes & diseases · 2024Article
- Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.World journal of gastrointestinal oncology · 2024Review
- Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy.Nature communications · 2024Article
- EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells.Frontiers in immunology · 2024Article
- Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors.Cancer research communications · 2023Article
- Discovery of Novel, Selective Prostaglandin EP4 Receptor Antagonists with Efficacy in Cancer Models.ACS medicinal chemistry letters · 2023Article
- The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy.Acta pharmaceutica Sinica. B · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 2 institutions in 1 country.
Yun WangDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Long CuiDepartment of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
Peter GeorgievDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Latika SinghDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Yanyan ZhengDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Ying YuDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Jeff GreinDepartment of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
Chunsheng ZhangDepartment of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
Eric S MuiseDepartment of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
David L SlomanDepartment of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
Heidi FergusonDepartment of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA.
Hongshi YuDepartment of Pharmaceutical Science, Merck & Co., Inc., Boston, Massachusetts, USA.
Cristina St PierreDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Pranal J DakleDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Vincenzo PucciDepartment of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA.
James BakerDepartment of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, Merck & Co., Inc., Boston, Massachusetts, USA.
Andrey LobodaDepartment of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
Doug LinnDepartment of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
Christopher BrynczkaDept. Safety and Exploratory Pharmacology, Safety Assessment and Laboratory Animal Resources, Merck & Co., Inc., Boston, Massachusetts, USA.
Doug WilsonDepartment of Genetics and Pharmacogenomics, Merck & Co., Inc., Boston, Massachusetts, USA.
Brian B HainesDepartment of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
Brian LongDepartment of Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts, USA.
Richard WnekDepartment of Translational Biomarkers, Merck & Co., Inc., Boston, Massachusetts, USA.
Svetlana SadekovaDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Michael RosenzweigDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Andrew HaidleDepartment of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
Yongxin HanDepartment of Discovery Chemistry, Merck & Co., Inc., Boston, Massachusetts, USA.
Sheila H RanganathDepartment of Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts, USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USQuantitative BioSciences · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostaglandin E
Indexed as
CD8-Positive T-LymphocytesReceptors, Prostaglandin E, EP4 SubtypeAnimalsCyclooxygenase 2DinoprostoneMacrophagesMiceCyclooxygenase 2DinoprostoneReceptors, Prostaglandin E, EP4 Subtypeep4 antagonismImmunotherapylymphocytesmyeloid cellspge2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.